InvestorsHub Logo
Followers 20
Posts 1059
Boards Moderated 0
Alias Born 04/01/2013

Re: DewDiligence post# 17321

Wednesday, 10/16/2013 3:28:02 PM

Wednesday, October 16, 2013 3:28:02 PM

Post# of 426700
The bad thing on the FDA viewpoint is the drug is safe and the trial is underway, no harm in approving conditionally. Why not? let doctors have options. Just seem so illogical to deny for the indication for the unknown CV outcome data.

Will FDA go back and extend all exclusivity once Reduce It is successful?

Bad decision, simple as that. Too bad. So Sad.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News